MP Biomedicals, Inc. Receives IND Approval to Commence Clinical Trials for Its HTLV-I/II Screening and Confirmatory Tests  
12/7/2010 9:50:30 AM

SANTA ANA, Calif.--(BUSINESS WIRE)--MP Biomedicals LLC announced today that it has received approval of its investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) to start pivotal clinical trials in the USA with the MP Diagnostics™ HTLV-I/II ELISA 4.0 and HTLV Blot.2.4. Studies will be conducted within the American Red Cross, the California Department of Public Health, and LABS, Inc. The company is working closely with the principal investigator of the American Red Cross sites, Dr. Susan Stramer, Executive Scientific Officer.